Blons H.,French Institute of Health and Medical Research |
Blons H.,University of Paris Descartes |
Rouleau E.,University Pierre and Marie Curie |
Charrier N.,Henri Mondor Albert Chenevier Hospitals |
And 23 more authors.
PLoS ONE | Year: 2013
Purpose:Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments. KRAS status has emerged as a negative predictor of clinical benefit from anti-EGFR antibodies in colorectal cancer, and anti-EGFR antibodies use was limited to KRAS wild type tumors. In order to ensure wide access to tumor molecular profiling, the French